Metallopanstimulin (MPS-1)/S27 ribosomal protein is involved in cellular proliferation and oncogenesis. In this study, we have examined the expression of the MPS-1 protein in 120 stages I and II breast carcinomas to study its relationship with breast cancer prognosis. We also determined if there was any relationship of MPS-1 with other biological markers commonly used in breast cancer prognosis. The expression of MPS-1 protein was analyzed by immunohistochemistry using specific anti-MPS-1 antibodies. We found that there was greater expression of MPS-1 in tumors of greater size and in higher histological grades. Thus, in tumors with more histological aggressiveness there is more MPS-1. Both were frequently associated with a greater proliferative activity. There was also a significant association between the expression of MPS-1 with the expression of receptors for progesterone (p=0.004), estrogens (p=0.03), bcl-2 (p=0.002), and MIB-1 (p=0.03). After univariate logistic regression analysis, we found that overexpression of MPS-1 correlated with Disease Free Survival (DFS) (p=0.039), showing that MPS-1 positivity is associated with a greater incidence of recurrence and/or metastasis. There was no association between overexpression of MPS-1 and poor Overall Survival (OS) (p=0.146). The results presented here indicate a significant correlation between overexpression of MPS-1/S27 ribosomal protein and more aggressive breast cancer growth. These results suggest that the MPS-1 antigen may be a useful marker to understand better the biological behavior of breast cancer.

Download full-text PDF

Source

Publication Analysis

Top Keywords

breast cancer
20
expression mps-1
16
mps-1
10
stages breast
8
mps-1/s27 ribosomal
8
ribosomal protein
8
mps-1 protein
8
cancer prognosis
8
associated greater
8
overexpression mps-1
8

Similar Publications

A narrative review of sleep and breast cancer: from epidemiology to mechanisms.

Cancer Causes Control

December 2024

Department of Clinical Nutrition, the First Affiliated Hospital of Anhui Medical University, 218 Jixi Road, Hefei, 230022, Anhui, China.

Breast cancer is the leading cause of cancer-related death and the most common cancer among women worldwide. It is crucial to identify potentially modifiable risk factors to intervene and prevent breast cancer effectively. Sleep factors have emerged as a potentially novel risk factor for female breast cancer.

View Article and Find Full Text PDF

Objective(s): Some forms of breast cancer such as triple-negative phenotype, are serious challenge because of high metastatic cases, high mortality and resistance to conventional therapy motivated the search for alternative treatment approaches. Nanomaterials are promising candidates and suitable alternatives for improving tumor and cancer cell treatments.

Materials And Methods: Biosynthesis of ZnO NPs by help of Berberis integerrima fruit extract, has been done.

View Article and Find Full Text PDF

Rearranged during transfection (RET) kinase is a validated therapeutic target for various cancers characterized by RET alterations. Although two selective RET inhibitors, selpercatinib and pralsetinib, have been approved by the FDA, acquired resistance through solvent-front mutations has been identified rapidly. Developing proteolysis targeting chimera (PROTAC) targeting RET mutations offers a promising strategy to combat drug resistance.

View Article and Find Full Text PDF

Polymer based nanoformulations offer substantial prospects for efficacious chemotherapy delivery. Here, we developed a pH-responsive polymeric nanoparticle based on acidosis-triggered breakdown of boronic ester linkers. A biocompatible hyaluronic acid (HA) matrix served as a substrate for carrying a doxorubicin (DOX) prodrug which also possesses natural affinity for CD44 cells.

View Article and Find Full Text PDF

Chimeric Peptide-Engineered Polyprodrug Enhances Cytotoxic T Cell Response by Inducing Immunogenic Cell Death and Upregulating Major Histocompatibility Complex Class I.

ACS Nano

December 2024

The Fifth Affiliated Hospital, Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, the School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, China.

Tumor-specific cytotoxic T cell immunity is critically dependent on effective antigen presentation and sustained signal transduction. However, this immune response is frequently compromised by the inherently low immunogenicity of breast cancer and the deficiency in major histocompatibility complex class I (MHC-I) expression. Herein, a chimeric peptide-engineered stoichiometric polyprodrug (PDPP) is fabricated to potentiate the cytotoxic T cell response, characterized by a high drug loading capacity and precise stoichiometric drug ratio, of which the immunogenic cell death (ICD) inducer of protoporphyrin IX (PpIX) and the epigenetic drug of decitabine (DAC) are condensed into a polyprodrug called PpIX-DAC.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!